vision loss

Key Takeaways Moorfields and UCL researchers treated nine adults with a rare eye disease in a first-in-human clinical trial. Average eye surface scores improved from 9.4 to 5.9 at three months and held at 6.7 after 12 months. Vision rose by about five chart lines on average, but the 95%